Close Menu

NEW YORK (GenomeWeb News) – French biomarker firm Skuldtech today announced it has been awarded €1 million ($1.3 million) in funding to support work on developing diagnostic tests for an Alzheimer's drug in development.

The funding is from Bpifrance, a French public financing structure, and is part of a project on Alzheimer's that has received €8.6 million in total funding. The program, Skuldtech said, is anticipated to last four years with the first results expected in 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.